192
Participants
Start Date
April 4, 2023
Primary Completion Date
April 3, 2025
Study Completion Date
April 3, 2030
Pembrolizumab+Carboplatin+albumin-bound paclitaxel:4 courses
"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab, Carboplatin, albumin-bound paclitaxel:4 cycles"
Pembrolizumab+Carboplatin+albumin-bound paclitaxel:2 courses
"Pembrolizumab,+Carboplatin+albumin-bound paclitaxel Pembrolizumab (IV), dose= 200mg , day=1 , cycle length: 21 days. Carboplatin (IV), dose=300mg/m2, day= 1, cycle length: 21 days. albumin-bound paclitaxel (IV), dose=260mg/m2, day= 1, cycle length: 21 days.~Intervention: Drug: Pembrolizumab , Carboplatin, albumin-bound paclitaxel:2 cycles"
RECRUITING
Sun yat-sen memorial hospital, Guangzhou
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER